Sanofi and GSK begin Phase I/II trial of Covid-19 vaccine
The vaccine combines Sanofi’s recombinant protein-based technology with GSK’s established pandemic adjuvant technology. Credit: Arek Socha from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more